Scientists have developed smart nanoparticles that can deliver antibiotics directly to Helicobacter pylori bacteria, which infect about half of the world's population and are a major cause of stomach ulcers and gastric cancer. While antibiotics are the usual treatment, they often struggle to reach bacteria that are hidden beneath the stomach's protective mucus layer or deep within ulcer tissue. This can lead to the need for higher doses, which increases the risk of side effects and the development of antibiotic resistance. To address this challenge, researchers from Pusan National University created a new type of nanoparticle designed to deliver antibiotics more effectively. The nanoparticles, made from a material called PLGA and coated with polydopamine, are loaded with clarithromycin, an antibiotic commonly used to treat H. pylori infections. These nanoparticles are designed to release the antibiotic in a controlled, multistage process. According to lead author Dr. Jin-Wook Yoo, the goal was to create a delivery system that could bypass the stomach's mucus barrier and target H. pylori precisely where they are located. The nanoparticles were made using a process called nanoprecipitation, followed by a surface coating with polydopamine. Their properties were thoroughly tested in laboratory and animal studies. In tests, the nanoparticles were able to remain stable in the acidic environment of the stomach, avoid releasing the antibiotic too early, and penetrate the mucus layer to reach ulcer tissue. They were found to accumulate specifically at the site of the infection and deliver the antibiotic about 400 micrometers into the ulcer, where H. pylori bacteria are deeply embedded. The polydopamine coating allowed the nanoparticles to stick to the bacteria without needing specific chemical signals, enabling the antibiotic to be released directly at the infection site. This targeted approach led to a nearly complete elimination of the bacteria, faster healing of ulcers, and improved tissue regeneration. The study showed that using these nanoparticles allowed researchers to achieve the same therapeutic effects with only one-tenth of the usual antibiotic dose, which could reduce side effects and the risk of resistance. Dr. Yoo suggests that this targeted delivery method could improve treatment outcomes and patient compliance. He also believes the platform could be adapted to treat other conditions where biological barriers hinder the effectiveness of traditional therapies. The findings were published in the Journal of Controlled Release on June 10, 2026.